Actively Recruiting
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
Led by Roswell Park Cancer Institute · Updated on 2026-01-02
106
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT, or definitive chemotherapy or chemotherapy-immunotherapy and will be considered separately as a single arm prospective cohort
CONDITIONS
Official Title
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Undergoing definitive or neoadjuvant chemoradiation therapy for confirmed esophageal adenocarcinoma
- Have an ECOG performance status of 0-1
- Able to swallow and retain oral medication, or have an enteric feeding tube for propranolol administration
- Participants of child-bearing potential must have a negative pregnancy test and agree to use effective contraception
- Understand the investigational nature of the study and sign informed consent prior to any study procedures
You will not qualify if you...
- Contraindications to beta-blockers such as uncontrolled depression, unstable angina, severe heart failure (NYHA Grade III or IV), hypotension (systolic BP <100 mmHg), severe asthma or COPD, uncontrolled diabetes (HbA1C >8.5 or fasting glucose >160 mg/dL), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma
- Current use of calcium channel blockers (non-dihydropyridines like verapamil) or rhythm control agents like digoxin and amiodarone
- Presence of pacemakers
- Uncontrolled illnesses including active infection, symptomatic congestive heart failure, unstable angina, psychiatric illness or social situations limiting compliance, cardiac arrhythmias (atrial fibrillation/flutter), severe bradycardia (heart rate <50 bpm or heart block)
- Pregnant or nursing females
- Unwilling or unable to follow protocol requirements
- Any condition deemed by the investigator to make the participant unsuitable for study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Actively Recruiting
Research Team
A
ASK RPCI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here